Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device Contract Manufacturing Market, 2019-2030”

The report features a comprehensive study on the current landscape of contract manufacturing service providers focused on medical devices (specifically for drug-delivery devices, diagnostic devices and therapeutic devices). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

·        A detailed review of the overall landscape of the medical device contract manufacturing market, featuring a list of CMOs engaged in this domain.

·        An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval, across different countries.

·        A benchmark analysis, highlighting the key focus areas of small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.

·        An analysis of the medical device supply-chain, highlighting the role of CMOs engaged in this domain.

·        Elaborate profiles of popular players that specialize in providing services for both precommercial and commercial scale manufacturing of medical devices.

·        A geographical clinical trial analysis of ongoing and planned studies related to medical devices.

·        A detailed analysis of the mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019.

·        An elaborate discussion on the future opportunities / trends related to the medical device contract manufacturing market.

·        A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Application areas

·        Therapeutic devices

·        Diagnostic devices

·        Drug delivery devices

·        Other devices

Device class

·        Class I medical devices

·        Class II medical devices

·        Class III medical devices

Therapeutic areas

·        Cardiovascular disorders

·        CNS disorders

·        Metabolic disorders

·        Oncological disorders

·        Orthopedic disorders

·        Ophthalmic disorders

·        Pain disorders

·        Respiratory disorders

·        Other therapeutic areas

Key geographical regions

·        North America

·        Europe

·        Asia Pacific

·        Rest of the world

Transcripts of interviews held with Raghu Vadlamudi (Chief Research and Technology Director, Donatelle) and Jan Wahlström (President and Chief Executive Officer, Elos Medtech)

Key companies covered in the report

·        Cirtec Medical

·        Creganna Medical

·        DynaFlex Technologies

·        Europlaz Technologies

·        Interplex

·        I-Tek Medical Technologies

·        Keystone Solutions Group

·        Modern Medical

·        Oscor

·        Providence Enterprise

·        Riverside Medical Packaging

·        SMC

·        Stellartech

·        Suzhou Jenitek

·        Synecco

·        Trelleborg Sealing Solutions

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/medical-device-contract-manufacturing-market-2019-2030/258.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Autoinjectors Market (3rd Edition), 2020-2030.”

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

·        A detailed assessment of the current market landscape of developers engaged in the development and / or manufacturing autoinjectors.

·        A detailed assessment of current landscape of companies that are developing drugs in combination with autoinjectors.

·        A competitiveness analysis of various disposable and reusable autoinjectors.

·        A detailed brand positioning analysis of leading industry players highlighting the current perceptions regarding their proprietary brands.

·        A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future.

·        A list of key opinion leaders (KOLs) within this domain with significant contributions in clinical trials and filing patent applications.

·        Detailed case studies on the most commonly targeted indications of the approved autoinjector products.

·        A case study on the role of CMOs offering services for drug delivery devices.

·        A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.

·        Elaborate profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Usability

·        Disposable

·        Reusable

Route of Administration

·        Subcutaneous

·        Intramuscular

Type of Molecule

·        Monoclonal Antibody

·        Peptide

·        Protein

·        Small Molecule

Therapeutic Indication

·        Anaphylaxis

·        Asthma

·        Multiple Sclerosis

·        Rheumatoid Arthritis

·        Migraine

·        Diabetes

·        Other Indications

Key Geographies

·        North America

·        Europe

·        Asia-Pacific

·        Rest of the World

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:

·        David Daily (CEO and Co-founder, DALI Medical Devices)

·        Dennis Lee (Senior Program Officer in CMC, Bill & Melinda Gates Foundation)

·        Douglas Marenzi (Managing Director, PHC Injection Technologies)

·        Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical)

·        Jesse Fourt (Design Director, IDEO)

Key companies covered in the report

·        Antares Pharma

·        Consort Medical (Previously Bespak)

·        DALI Medical Devices

·        Elcam Medical (E3D Elcam Drug Delivery Devices)

·        Jiangsu Delfu Medical Devices

·        Oval Medical Technologies

·        Owen Mumford

·        SHL Group

·        Union Medico®

·        Ypsomed

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Drug Conjugates Market (5th Edition), 2019-2030.”

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

·        A detailed assessment of the current market landscape of ADCs.

·        Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios.

·        An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.

·        A list of key opinion leaders (KOLs) within this domain.

·        An insightful competitiveness analysis of biological targets.

·        An analysis of the partnerships that have been established in the recent past.

·        An analysis of the investments made.

·        A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April).

·        An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch.

·        An analysis of the key promotional strategies that have been adopted by the developers of marketed products.

·        An assessment of the various therapeutics that are being evaluated in combination with ADCs.

·        A review of the evolution of ADC conjugation technologies.

·        An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs.

·        An elaborate discussion on various factors that form the basis for the pricing of ADC products.

·        A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.

·        A case study on companies offering companion diagnostics.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Type of payload

·        MMAE

·        DM4

·        Camptothecin

·        AM1

·        MMAF

Type of linker

·        VC

·        Sulfo-SPDB

·        SMCC

·        VA

·        Hydrazone linker

·        Others

Target Indications

·        Breast Cancer

·        Lymphoma

·        Leukemia

·        Urothelial cancer

·        Lung cancer

·        Ovaria cancer

·        Others

Target Antigen

·        CD30

·        HER2

·        CD22

·        CD33

·        Others

·        Small Molecule

Technology Providers

·        Seattle Genetics

·        ImmunoGen

·        StemCentRx

·        Immunomedics

·        Others

Key Geographies

·        North America

·        Europe

·        Asia Pacific

Transcripts of interviews held with the following senior level representatives of stakeholder companies:

·        Alan Burnett (Professor, School of Medicine, Cardiff University)

·        Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)

·        Anthony DeBoer (Director, Business Development, Synaffix)

·        Christian Bailly (Director of CDMO, Pierre Fabre)

·        Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)

·        Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)

·        John Burt (Chief Executive Officer, Abzena)

·        Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)

·        Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)

·        Mark Wright (Site Head, Piramal Healthcare)

·        Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)

·        Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)

·        Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai)

·        Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)

Key companies covered in the report

·        Bristol Myers Squibb

·        AbbVie

·        Astellas Pharma

·        AstraZeneca

·        Daiichi Sankyo

·        Pfizer

·        Roche / Genentech

·        Synthon

·        Bayer HealthCare

·        Biotest Pharmaceuticals

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

The USD 2.7 billion and USD 600 million (by 2030) financial opportunity within the large volume wearable injectors market for the delivery of insulin and of non-insulin drugs, respectively, has been analyzed across the following segments:

Key Inclusions

·        An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump / injector and infusion pump / injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle / cannula and needle / catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device / personal diabetes manager (PDM) / smartphone) in the insulin delivery devices.

·        A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems (in case of insulin devices).

·        Elaborate profiles of the prominent companies that develop large volume wearable injectors. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products.

·        An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, service agreements, and other relevant types of deals.

·        A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2000, and offering a means for other industry stakeholders to identify potential acquisition targets.

·        An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors over the last three decades. It also highlights the key parameters associated with the patents, including information on patent type, issuing authority / patent offices involved, Cooperative Patent Classification (CPC) symbols, emerging areas (in terms of number of patents filed / granted), company type and leading industry, non-industry and individual patent assignees (in terms of size of intellectual property portfolio).

·        A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).

·        A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform in the last few years.

·        A detailed analysis of completed, ongoing and planned clinical trials of various large volume wearable injector products based on the various relevant parameters, such as trial registration year, current trial phase, trial status, study design, study focus, targeted therapeutic area and clinical outcomes.

·        A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of wearable injectors. It includes information on the services provided by contract service providers for manufacturing of various device components (primary containers), infusion sets, adhesives, closures and injection moldings.

·        An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.

·        Informed estimates of the existing market size and the future opportunity for large volume wearable injectors, over the next decade. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an estimate on the likely evolution of the large volume wearable injectors market, for the delivery of both insulin and non-insulin drugs, over the period 2020-2030.

The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Type of Device

·        Patch Pump / Injectors

·        Infusion Pump / Injectors

Product Usability

·        Disposable

·        Re-usable

Therapeutic Area (for non-insulin drugs)

·        Neurological Disorders

·        Cardiovascular Disorders

·        Oncological Disorders

·        Infectious Disorders

Key geographical regions

·        North America

·        Europe

·        Asia Pacific

The report features inputs from eminent industry stakeholders, according to whom, large volume injectors are generally preferred for the delivery of biologics, which cannot be easily administered orally. The report includes detailed transcripts of discussions held with the following experts:

·        Mark Banister (CEO, Medipacs)

·        Michael Hooven (CEO, Enable Injections)

·        Jesper Roested (CEO, Subcuject)

·        Pieter Muntendam (Former President and CEO, scPharmaceuticals)

·        Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)

·        Graham Reynolds (Vice President and General Manager, Biologics, West Pharmaceutical Services)

·        Mindy Katz (Director of Product, Sorrel Medical)

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Key Inclusions

·        An overview of the current market landscape of the handheld ultrasound imaging devices, providing information on the status of development, application area (abdomen, cardiac, gynecological, pulmonary, urological scanning and others), weight of device, type of transducer array (convex / curved, linear, micro-convex, transvaginal, phased and others), transducer frequency, mode of imaging (brightness, color doppler, motion, power doppler, pulsed wave, tissue harmonic and others), field of view, scanning depth, type of software (smartphone application and customized software application), connectivity provision (universal serial bus (USB), cellular / WiFi and bluetooth), data management feature(s) (internal, external, and cloud / remote monitoring), battery backup and cost of device. In addition, it presents details of the device developers, highlighting year of establishment, company size, type of business model used (B2B and B2C), target market (domestic and domestic and international) and location of headquarters. Further, it highlights the key initiatives taken by the various device developers to tackle the on-going global pandemic of COVID-19.

·        An in-depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of handheld ultrasound imaging devices, based on the parameters, such as application area, mode of imaging, number of devices and company size, [B] a grid representation illustrating the distribution of scanners based on application area, type of transducer array and type of software, [C] an insightful heat map representation, highlighting the distribution of devices on the basis of application area and mode of imaging, and [D] a tree map representation of the handheld ultrasound imaging devices, distributed on the basis of mode of imaging and connectivity provision.

·        Elaborate profiles of mid-sized / large companies that are engaged in the development of handheld ultrasound imaging scanners. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.

·        A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength of product portfolio, type of software, mode of imaging, connectivity provisions, geographical presence / reach and supplier power of each company.

·        An analysis of the partnerships that have been inked by stakeholders in the domain, during the time period 2010-2020 (till April), covering licensing agreements, acquisitions and mergers, research and development agreements, product distribution agreements and other relevant types of deals.

·        An insightful analysis highlighting cost saving potential associated with the use of handheld ultrasound imaging devices, based on information from close to 50 countries, taking into consideration various parameters, such as total number of radiologists, annual salary, number of ultrasound scans performed and increase in efficiency by adoption of these handheld ultrasound imaging devices.

·        An informed estimate of the global demand for handheld ultrasound imaging devices for the period 2020-2030, taking into account the impact of COVID-19, historical sales of these devices, and annual revenues (generated by sales of these devices) of prominent device manufacturers.

·        A review of the product distribution strategies adopted by different device-developers, demand and market attractiveness for handheld ultrasound imaging devices across different types of end-users, including ambulatory surgical centers, diagnostic imaging centers, hospitals, maternity clinics, specialty clinics, and other end-users.

·        An insightful discussion on the impact of COVID-19 on the overall handheld ultrasound imaging devices market, along with the key lessons learnt from big pharma players in 2008 recession.

·        An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till April) and insights from the recent news articles related to handheld ultrasound imaging devices, indicating the increasing popularity of this domain.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Application Area

·        Cardiac Scanning

·        Emergency Medicines

·        Gynecological / Obstetrics Scanning

·        Musculoskeletal Scanning

·        Pulmonary Scanning

·        Urological Scanning

·        Vascular Surgery

·        Other Application Areas

Type of Transducer Array

·        Curved

·        Endocavity

·        Linear

·        Phased

·        Other Scanners

Type of Software

·        Smartphone Applications

·        Customized Software

End-Users

·        Ambulatory Surgical Centers

·        Diagnostic Imaging Centers

·        Hospitals

·        Maternity Clinics

·        Specialty Clinics

·        Other End-Users

Key Geographical Regions

·        North America

·        Europe

·        Asia-Pacific and the Rest of the World

The report includes detailed transcripts of discussions held with the following experts:

·        Stefan Maas (Chief Executive Officer, SomaView)

·        Anais Concepcion (Director of Content and Campaign Management, EchoNous)

·        Zhengzheng Zhu (Oversea Business Development, PeakSonic)

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Key Inclusions

·        A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment.

·        A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration the early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above) development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and size of the developer company. In addition, it consists of a schematic world map representation, highlighting the geographical locations of technology developers engaged in this domain.

·        Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics. Each profile features an overview of the drug, details of the developer, along with its financial performance, mechanism of action and targets, dosage information, current clinical development status, development process, as well as details on annual sales (wherever available).

·        Key takeaways from the bispecific antibody therapeutics pipeline, featuring a [A] grid analysis, representing the distribution of the pipeline (on the basis of mechanisms of action of product candidates) across different therapeutic areas and stages of development, [B] a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on a number of relevant parameters, including number of bispecific antibodies in early stage (phase I) and late stage of development (phase II and above), number of ongoing clinical trials, target therapeutic areas and the number of companies that are developing these molecules, [C] a two-dimensional scattered plot competitiveness analysis, for the various target combinations for clinical-stage bispecific antibodies and [D] the chapter also includes an insightful summary representation using the logos of different industry stakeholders, highlighting the distribution of companies based on the company size.

·        An analysis of the big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action and target therapeutic area.

·        An analysis of recent partnerships and collaboration agreements inked in this domain since 2016, covering research collaborations, product and technology licensing agreements, product development and commercialization agreements, manufacturing agreements, mergers / acquisitions, joint ventures, product development agreements and other deals.

·        A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, it includes a list of contract manufacturing organizations (CMOs) and contract research organizations (CROs). The chapter also highlights the key considerations for bispecific antibody developers while selecting a suitable CRO / CMO.

·        A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics, taking into consideration a number of relevant parameters, including trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial.

·        A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies, namely Blincyto® and Hemlibra®. It includes a detailed comparison of both the drugs based on the information available on their respective websites, such as patient support offerings, informative downloadable content, and product visibility in scientific conferences.

·        A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Therapeutic Area

·        Autoimmune Disorders

·        Eye Disorders

·        Genetic Disorders

·        Hematological Malignancies

·        Infectious Diseases

·        Inflammatory Disorders

·        Skin Disorders

Mechanism of Action

·        Cytokines Retargeting / Neutralization

·        Dual Ligands Blocking

·        T-cell Retargeting / Activation

·        Others

Target Antigens

·        CD3 x CD19

·        CD30 x CD16A

·        Factor IXa x Factor X

·        IL-1α x IL-1β

·        IL-13 x IL-4

·        IL-17A x Albumin

·        IL-17A x IL-17F

·        Psl x PcrV

·        VEGF-A x ANG2

·        Others

Key Players

·        Astra Zeneca

·        Amgen

·        AbbVie

·        Affirmed

·        Affibody

·        Merck

·        Roche

·        Sanofi

·        Taisho Pharmaceutical

Key Geographical Regions

·        North America

·        Europe

·        Asia-Pacific

The report features inputs from eminent industry stakeholders, according to whom this relatively novel class of antibody therapeutics is likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts:

·        Martin Steiner (Chief Executive Officer, Synimmune)

·        Ludger Große-Hovest (Chief Scientific Officer, Synimmune)

·        Jane Dancer (Chief Business Officer, F-Star)

·        Siobhan Pomeroy (Senior Director, Business Development, Cytom X)

·        Yinjue Wang (Associate Director, Process Development, Innovent Biologics)

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments:

Type of Product Manufactured

·        Active Pharmaceutical Ingredients (APIs)

·        Finish Drug Formulations (FDFs)

Type of Type of Formulation

·        Solid Formulations

·        Oral Liquids

·        Injectables

·        Others

Scale of Operation

·        Clinical

·        Commercial

Company Size

·        Small-sized

·        Mid-sized

·        Large

Key Geographical Regions

·        North America

·        Europe

·        Asia-Pacific and Rest of the World

The Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

·        Bristol Myers Squibb

·        GlaxoSmithKline

·        Incyte

·        Novartis

·        Trillium Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Profiles

6. Regional Capability Analysis

7. Likely Partner Analysis

8. Clinical Trial Analysis

9. Capacity Analysis

10. Demand Analysis

11. Make versus Buy Decision Making Framework

12. Microbiome related initiatives of Big Pharmaceutical Players

13. Market Forecast

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

18. Appendix 3: List of Probiotic Supplement Contract Manufacturers and

Microbial Contract Service Providers

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

The USD 2.7 billion and USD 600 million (by 2030) financial opportunity within the large volume wearable injectors market for the delivery of insulin and of non-insulin drugs, respectively, has been analyzed across the following segments:

Type of Device

·        Patch Pump / Injectors

·        Infusion Pump / Injectors

Product Usability

·        Disposable

·        Re-usable

Therapeutic Area (for non-insulin drugs)

·        Neurological Disorders

·        Cardiovascular Disorders

·        Oncological Disorders

·        Infectious Disorders

Key geographical regions

·        North America

·        Europe

·        Asia Pacific

The report Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices features the following companies, which we identified to be key players in this domain:

·        Becton Dickinson

·        Bespak (subsidiary of Consort Medical)

·        CeQur

·        Debiotech

·        Eli Lilly

·        Enable Injections

·        Insulet

·        Medtronic

·        PharmaSens

·        Roche

·        SOOIL Development

·        Sonceboz

·        Sensile Medical (acquired by Gerresheimer)

·        SteadyMed Therapeutics (acquired by United Therapeutics)

·        Tandem Diabetes Care

·        Weibel CDS (acquired by SHL Medical)

·        West Pharmaceutical Services

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Large Volume Wearable Injectors: Current Market Landscape

5. Product Competitiveness Analysis

6. Large Volume Wearable Injectors: Key Players

7. Drug Device Combinations: Tabulated Profiles

8. Partnerships and Collaborations

9. Key Acquisition Targets

10. Patent Analysis

11. Large Volume Wearable Injectors: Likely Drug Candidates

12. Emerging Trends on Social Media

13. Clinical Trial Analysis

14. Case Study: Role of CMOs in Device Development and Manufacturing

15. Regulatory and Reimbursement Landscape for Medical Devices

16. Market Sizing and Opportunity Analysis

17. SWOT Analysis

18. Executive Insights

19. Appendix 1: Tabulated Data

20. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

The USD 1.1 billion (by 2030) financial opportunity within the Handheld Ultrasound Imaging Devices Market has been analyzed across the following segments:

Application Area

·        Cardiac Scanning

·        Emergency Medicines

·        Gynecological / Obstetrics Scanning

·        Musculoskeletal Scanning

·        Pulmonary Scanning

·        Urological Scanning

·        Vascular Surgery

·        Other Application Areas

Type of Transducer Array

·        Curved

·        Endocavity

·        Linear

·        Phased

·        Other Scanners

Type of Software

·        Smartphone Applications

·        Customized Software

End-Users

·        Ambulatory Surgical Centers

·        Diagnostic Imaging Centers

·        Hospitals

·        Maternity Clinics

·        Specialty Clinics

·        Other End-Users

Key Geographical Regions

·        North America

·        Europe

·        Asia-Pacific and the Rest of the World

For more information, please visit https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html

The Global Handheld Ultrasound Imaging Devices Market, 2020-2030, report features the following companies, which we identified to be key players in this domain:

·        Aidmax Medical

·        Beijing Konted Medical Technology

·        Biim Ultrasound

·        BreastIT

·        Butterfly Network

·        CJ Medical

·        Clarius Mobile Health

·        EchoNous

·        Fujifilm

·        GE Healthcare

·        Guangzhou Top Medical Equipment

·        Healcerion

·        Interson Medical Instruments

·        Philips

·        Somax Systems

·        VINNO

·        WuHan Youkey Bio-Medical Electronics

·        Yor Labs

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Profiles

6. Brand Positioning Analysis of Key Players

7. Partnerships and Collaborations

8. Cost Saving Analysis

9. Demand Analysis

10. Market Forecast

11. End-User Specific Opportunity Analysis

12. Case Study: Impact of Coronavirus Outbreak

13. Conclusion

14. Executive Insights

15. Appendix 1: Tabulated Data

16. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Key Inclusions

·        A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, key therapeutic areas (cardiovascular disorders, muscular disorders, neurological disorders, ocular disorders, oncology and others) and target disease indication(s), information on gene type, type of vector used, type of therapy (ex vivo and in vivo), mechanism of action, type of gene modification (gene augmentation, oncolytic viral therapy and others) and special drug designation (if any).

·        A discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vectors.

·        A world map representation, depicting the most active geographies, in terms of the presence of companies engaged in developing gene therapies, and a bull's eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy (ex vivo and in vivo).

·        A discussion on the regulatory landscape related to gene therapies across various geographies, namely North America (the US and Canada), Europe and Asia-Pacific (Australia, China, Japan and South Korea), providing details related to the various challenges associated with obtaining reimbursements for gene therapies.

·        Detailed profiles of marketed and phase II/III and gene therapies, including a brief history of development, information on current development status, mechanism of action, affiliated technology, strength of patent portfolio, dosage and manufacturing details, along with information on the developer company.

·        An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development, namely prior to drug launch, at / during drug launch and post-marketing.

·        A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies, featuring detailed profiles of technologies that were / are being used for the development of four or more products / product candidates.

·        An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016. The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC classification, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.

·        An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019. The analysis also provides information on the key value drivers and deal multiples related to the mergers and acquisitions that we came across.

·        An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.

·        An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of gene therapies under development, funding information, partnership activity and strength of patent portfolio.

·        A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors. The study also includes a detailed discussion on the manufacturing processes associated with various types of vectors.

·        A discussion on the various operating models adopted by gene therapy developers for supply chain management, highlighting the stakeholders involved, factors affecting the supply of therapeutic products and challenges encountered by developers across the different stages of the gene therapy supply chain.

·        An analysis of the various factors that are likely to influence the pricing of gene-based therapies, featuring different models / approaches that may be adopted by manufacturers to decide the prices of these therapies.

For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Key therapeutic areas

·        Autoimmune disorders

·        Cardiovascular diseases

·        Genetic disorders

·        Hematological disorders

·        Metabolic disorders

·        Ophthalmic disorders

·        Oncological disorders

·        Others

Type of vector

·        Adeno associated virus

·        Adenovirus

·        Herpes simplex virus type 1

·        Lentivirus

·        Plasmid DNA

·        Retrovirus

·        Vaccinia Virus

Type of therapy

·        Ex vivo

·        In vivo

Type of gene modification

·        Gene augmentation

·        Immunotherapy

·        Oncolytic therapy

·        Others

Route of administration

·        Intraarticular

·        Intracerebellar

·        Intramuscular

·        Intradermal

·        Intravenous

·        Intravitreal

·        Intravesical

·        Subretinal

·        Others

Key geographical regions

·        North America

·        Europe

·        Asia-Pacific

The report includes detailed transcripts of discussions held with the following experts:

·        Adam Rogers (CEO, Hemera Biosciences)

·        Al Hawkins (CEO, Milo Biotechnology)

·        Buel Dan Rodgers (Founder & CEO, AAVogen)

·        Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)

·        Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)

·        Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)

·        Jeffrey Hung (CCO, Vigene Biosciences)

·        Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)

·        Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)

·        Robert Jan Lamers (CEO, Arthrogen)

·        Tom Wilton (Chief Business Officer, LogicBio Therapeutics)

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com